24小时热门版块排行榜    

查看: 552  |  回复: 3

984208320

木虫 (正式写手)

[交流] 【Share】Malaria: New Partnership Aims to Stop Parasite in its Tracks

A new partnership is being launched to develop a malaria vaccine that would prevent parasites from entering the liver. Most of the symptoms of the disease develop after parasites have had time to replicate there.

The World Health Organization estimates that in 2008, there were 247 million cases of malaria worldwide, with one million deaths. It says in Africa, a child dies every 45 seconds from the disease.

The best treatment now available is artemisinin-based combination therapy. But an effective vaccine would be much better. That's the goal of the partnership involving the international, non-profit organization PATH, Merck Pharmaceuticals and New York University.

Finding a weakness

Scientists think they've discovered the Achilles heel of the malaria parasite. After a bite by an infected mosquito, the parasite travels through the bloodstream and arrives at the liver. That's where scientists believe the best line of defense can be made.

Dr. Ashley Birkett is PATH's Malaria Vaccine Initiative director of pre and early clinical development.

"The parasite has a natural affinity for liver cells. Liver cells are the cells that the parasite can actually make copies of itself in once it enters the human body. So, it's goal once it enters the human bloodstream after an infectious bite is to find liver cells. And then it enters those liver cells through a set of specific interactions that we don't fully understand. But there is a critical event in that entry process that we think we can target through a vaccine approach," he says.

He says if the parasite cannot enter the liver, it cannot replicate and cause disease. But targeting a parasite is more difficult than targeting viruses or bacteria.

"This is a parasite," he says, "It's a very complex organism that has over 5,000 different gene products that it makes. It's a lot more complicated than a typical virus. I think also there have been limited resources that have been applied to malaria vaccine development over the years. But we are having significant success now. And through a partnership with GlaxoSmithKline, PATH MVI is engaged in a very large phase-three clinical study, which is a last stage of clinical testing before a vaccine can actually be licensed and start saving lives."

Birkett says the vaccine has been evaluated in 16,000 young children in seven sub-Saharan African countries. It has an efficacy rate of 50 percent.

"So, given that we're looking in the order of 900,000 deaths from malaria in young children primarily per year in sub-Saharan Africa, a vaccine with 50 percent efficacy is actually a very significant achievement. But we want to do better," says Birkett.

The vaccine being tested depends on the body producing very large numbers of antibodies against the malaria parasite. That's makes it more difficult to have a higher efficacy rate. The hope of a new vaccine is to specifically target a different area of the parasite with fewer anti-bodies.

Malaria taking a toll

Dr. Birkett says this would relieve African countries of some heavy burdens.

"We're looking at countries in sub-Saharan Africa, which already have significant burdens to deal with in terms of economic impact of these global infectious diseases. And malaria has a huge economic impact. So a vaccine that can be highly protective and prevent these clinical diseases and up to 900,000 deaths per year is going to have a significant health and economic benefit in these countries," he says.

Dr. Birkett says the cost of such a vaccine would be kept as low as possible. Clinical testing on the proposed vaccine is still three or four years away. Malaria immunization would be included as part of a child's routine vaccinations.
回复此楼

» 猜你喜欢

已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

小木虫(沙发+1,金币+0.5):恭喜抢个沙发,再给个红包
2楼2010-12-15 10:24:20
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

小木虫(金币+0.2):抢了个小板凳,给个红包
3楼2010-12-15 10:24:21
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
4楼2010-12-15 21:35:27
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 984208320 的主题更新
普通表情 高级回复 (可上传附件)
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[考研] 一志愿中国石油大学(华东) 本科齐鲁工业大学 +3 石能伟 2026-03-17 3/150 2026-03-21 02:22 by JourneyLucky
[考研] 328求调剂,英语六级551,有科研经历 +4 生物工程调剂 2026-03-17 8/400 2026-03-21 02:12 by JourneyLucky
[考研] 085700资源与环境308求调剂 +12 墨墨漠 2026-03-18 13/650 2026-03-21 01:42 by JourneyLucky
[考研] 294求调剂材料与化工专硕 +15 陌の森林 2026-03-18 15/750 2026-03-20 23:28 by JourneyLucky
[考研] 求调剂,一志愿:南京航空航天大学大学 ,080500材料科学与工程学硕,总分289分 +4 @taotao 2026-03-19 4/200 2026-03-20 22:14 by JourneyLucky
[考研] 265求调剂 +12 梁梁校校 2026-03-19 13/650 2026-03-20 21:01 by 无际的草原
[论文投稿] 申请回稿延期一个月,编辑同意了。但系统上的时间没变,给编辑又写邮件了,没回复 10+3 wangf9518 2026-03-17 4/200 2026-03-19 23:55 by babero
[考研] 一志愿中国海洋大学,生物学,301分,求调剂 +5 1孙悟空 2026-03-17 6/300 2026-03-19 23:46 by zcl123
[考博] 申博26年 +3 八6八68 2026-03-19 3/150 2026-03-19 19:43 by nxgogo
[考研] 材料与化工求调剂 +7 为学666 2026-03-16 7/350 2026-03-19 14:48 by 尽舜尧1
[考研] 085600材料与化工求调剂 +6 绪幸与子 2026-03-17 6/300 2026-03-19 13:27 by houyaoxu
[考研] 本科郑州大学物理学院,一志愿华科070200学硕,346求调剂 +4 我不是一根葱 2026-03-18 4/200 2026-03-19 09:11 by 浮云166
[考研] 0703化学 305求调剂 +4 FY_yy 2026-03-14 4/200 2026-03-19 05:54 by anny19840123
[考研] 311求调剂 +11 冬十三 2026-03-15 12/600 2026-03-18 14:36 by 星空星月
[考研] 304求调剂 +12 小熊joy 2026-03-14 13/650 2026-03-18 12:34 by Linda Hu
[考研] 293求调剂 +11 zjl的号 2026-03-16 16/800 2026-03-18 08:10 by zhukairuo
[考研] 一志愿,福州大学材料专硕339分求调剂 +3 木子momo青争 2026-03-15 3/150 2026-03-17 07:52 by laoshidan
[考研] 中科院材料273求调剂 +4 yzydy 2026-03-15 4/200 2026-03-16 15:59 by Gaodh_82
[考研] 0856求调剂 +3 刘梦微 2026-03-15 3/150 2026-03-16 10:00 by houyaoxu
[考研] 289求调剂 +4 这么名字咋样 2026-03-14 6/300 2026-03-14 18:58 by userper
信息提示
请填处理意见